Sfoglia per AUTORE
MARCHETTI C
Collezione AO Ordine Mauriziano
Items : 3
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial. in Gynecologic oncology / Gynecol Oncol. 2023 May;172:72-77. doi: 10.1016/j.ygyno.2023.03.011. Epub 2023 Mar 23.
2023
AO Ordine Mauriziano
AO Ordine Mauriziano
Musacchio L; Turinetto M; Arenare L; Bartoletti M; Califano D; Tuninetti V; Marchetti C; Cormio G; Loizzi V; Pisano C; Salutari V; Valabrega G; Priolo D; Cecere SC; Ventriglia J; Raspagliesi F; Perrone F; Fagotti A; Lorusso D; Scambia G; Pignata S;
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study. in Cancers / Cancers (Basel). 2023 Dec 20;16(1):41. doi: 10.3390/cancers16010041.
2023
AO Ordine Mauriziano
AO Ordine Mauriziano
Turinetto M; Ricotti A; Marchetti C; Pisano C; Zamagni C; Cassani C; Malaguti P; Baldoni A; Scollo P; Scandurra G; Parisi A; Artioli G; Palaia I; Vertechy L; Bergamini A; Picardo E; Tuninetti V; Scotto G; Scambia G; Pignata S; Valabrega G;
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis. in Cancer treatment reviews / Cancer Treat Rev. 2022 Nov;110:102458. doi: 10.1016/j.ctrv.2022.102458. Epub 2022 Aug 24.
2022
AO Ordine Mauriziano
AO Ordine Mauriziano
Musacchio L; Valsecchi AA; Salutari V; Valabrega G; Camarda F; Tuninetti V; Giannone G; Bartoletti M; Marchetti C; Pignata S; Fagotti A; Scambia G; Di Maio M; Lorusso D;